Vanda Pharmaceuticals | VNDA - Equity Capital And Reserves


Vanda Pharmaceuticals reported $327.19M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
J&J USD 81.19B 358M Mar/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Moderna USD 7.41B 1.24B Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Takeda JPY 7.77T 129.5B Mar/2026
Teva Pharmaceutical Industries USD 8.23B 314M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Veracyte USD 1.34B 34.83M Mar/2026